CD40 and plasma cell myeloma: Furthermore, the interaction between CD40 and its natural ligand (CD40L, CD154) was shown to modulate the growth of malignant B cells, thus CD40-related therapies have been considered for a range of cancer entities, including B-cell malignancies, leukemia, and multiple myelomas (MMs) (108), making it an attractive target structure.